← All trials
NCT05623488
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 31, 2023
- Primary completion
- Jan 31, 2025
- Completion date
- Jan 31, 2038
- First posted
- Nov 21, 2022
- Last posted
- Nov 21, 2022
- Enrollment
- 12
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of PennsylvaniaLead sponsor
- University of PennsylvaniaOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.